Ibrutinib for Chronic Graft-Versus-Host Disease

Abstract


 No eligible evidence was identified comparing ibrutinib to another intervention for the management of treatment-refractory chronic graft-versus-host disease.
 Currently available evidence describing second- or third-line therapies for treatment-refractory chronic graft-versus-host disease was ineligible for this review because of the use of non-comparative research methods (i.e., single-arm trials, case series, and case reports).
 One randomized controlled trial is currently under way investigating the use of ibrutinib as first-line therapy for chronic graft-versus-host disease; however, no randomized controlled trials of ibrutinib for the management of treatment-refractory chronic graft-versus-host disease are currently being conducted.
 The need for high-quality randomized controlled trials of ibrutinib for treatment-refractory chronic graft-versus-host disease has been highlighted repeatedly in recent literature.